Effects of Olanzapine Plasma Concentrations on Depressive Symptoms in Schizophrenia: A Pilot Study

Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

“…The reviewed studies strongly indicate a relationship between clinical outcomes and plasma OLZ concentrations (Perry et al, 1997[118]; Lane et al, 2002[78]; Mauri et al, 2005[96]). Furthermore, given the large inter-patient variability in plasma OLZ levels at the same doses, the monitoring of blood OLZ concentrations can be considered very useful in assessing therapeutic efficacy and controlling adverse events.…”

“…Furthermore, given the large inter-patient variability in plasma OLZ levels at the same doses, the monitoring of blood OLZ concentrations can be considered very useful in assessing therapeutic efficacy and controlling adverse events. A therapeutic range of between 20 ng/ml and 50 ng/ml has been found (Lane et al, 2002[78]; Fellows et al, 2003[50]; Mauri et al, 2005[96]).…”

Very-high-dose olanzapine for treatment-resistant schizophrenia

“…Mauri et al described a curvilinear relationship with clinical efficacy between 20 and 50 ng/ml of olanzapine serum concentration [15]. Lane et al, however, failed to establish any correlation between olanzapine blood level and improvements in schizophrenic symptoms, although they did find one for depressive symptoms, with a plasma concentration of 36 ng/ml being a good predictor of response [16]. We can hypothesize that olanzapine's serotonin antagonism plays a key role in the antidepressant effect.…”

Clinical Pharmacology of Dopamine-Modulating Agents in Tourette’s Syndrome

“…daily dose and plasma concentration, but close to 9-OH-RSP (Aravagiri, Marder, Nuechterlein, & Gitlin, 2003) Renal excretion with 9-OH-risperidone as the major compound and only 4% unchanged, Minor compound (14%) excreted by feces (Byerly & DeVane, 1996;Mauri et al, 2007) (Baldessarini, 1996) Mainly by 9-hydroxylation in liver: 9-OH-RSP (Mannens et al, 1993) CYP2D6, Lesser extend: CYP3A4 (Mannens et al, 1993) Aripiprazole 87% (Winans, 2003) Well resorbed (Mallikaarjun, Salazar, & Bramer, 2004) After 3-5 h (OA) (Mallikaarjun et al, 2004) Extensively bound to plasma proteins >99% (mainly albumin; DeLeon, Patel, & Crismon, 2004) Steady state after 14 days (Mallikaarjun et al, 2004) Vd: 404 l (4.9 l/kg) (Mallikaarjun et al, 2004) Kidney and liver excretion, 25% recovered in urine (<1% unchanged); 55% in feces (18% unchanged) ( (Callaghan et al, 1999) After 6 h (Callaghan et al, 1999) 93%, mainly albumin 90% and a1-glycoporotein 77% (Callaghan et al, 1999) Vd: 16 AE 5 l/kg, plasma clearance: 26 l/h, range 12-47 l/h, (Callaghan et al, 1999), CYP1A2 (Kassahun et al, 1997) therapeutic range: 20 ng-50 ng/ml (Fellows et al, 2003;Lane et al, 2002;Mauri et al, 2005;Perry, Lund, Sanger, & Beasley, 2001) Smokers and men: greater clearance (Callaghan et al, 1999), 87% excreted, 30% feces, 57% urine (Kassahun et al, 1997) Mean: 33 h, (range 21-54 h); men increased clearance compared to women; smokers have a 20% shorter elimination halflife …”